The Women’s Ischemia Syndrome Evaluation (WISE) Study: Protocol Design, Methodology and Feasibility Report

C. Noel Bairey Merz, MD, FACC,*† Sheryl F. Kelsey, PhD,‡ Carl J. Pepine, MD, FACC,§ Nathaniel Reichek, MD, FACC,¶ Steven E. Reis, MD, FACC,‖ William J. Rogers, MD, FACC,# Barry L. Sharaf, MD, FACC,** George Sopko, MD,†† for the WISE Study Group
Los Angeles, California; Pittsburgh, Pennsylvania; Gainesville, Florida; Birmingham, Alabama; Providence, Rhode Island, and Bethesda, Maryland

OBJECTIVES
The Women’s Ischemia Syndrome Evaluation (WISE) is a National Heart, Lung and Blood Institute–sponsored, four-center study designed to: 1) optimize symptom evaluation and diagnostic testing for ischemic heart disease; 2) explore mechanisms for symptoms and myocardial ischemia in the absence of epicardial coronary artery stenoses, and 3) evaluate the influence of reproductive hormones on symptoms and diagnostic test response.

BACKGROUND
Accurate diagnosis of ischemic heart disease in women is a major challenge to physicians, and the role reproductive hormones play in this diagnostic uncertainty is unexplored. Moreover, the significance and pathophysiology of ischemia in the absence of significant epicardial coronary stenoses is unknown.

METHODS
The WISE common core data include demographic and clinical data, symptom and psychosocial variables, coronary angiographic and ventriculographic data, brachial artery reactivity testing, resting/ambulatory electrocardiographic monitoring and a variety of blood determinations. Site-specific complementary methods include physiologic and functional cardiovascular assessments of myocardial perfusion and metabolism, ventriculography, endothelial vascular function and coronary angiography. Women are followed for at least 1 year to assess clinical events and symptom status.

RESULTS
In Phase I (1996–1997), a pilot phase, 256 women were studied. These data indicate that the WISE protocol is safe and feasible for identifying symptomatic women with and without significant epicardial coronary artery stenoses.

CONCLUSIONS
The WISE study will define contemporary diagnostic testing to evaluate women with suspected ischemic heart disease. Phase II (1997–1999) is ongoing and will study an additional 680 women, for a total WISE enrollment of 936 women. Phase III (2000) will include patient follow-up, data analysis and a National Institutes of Health WISE workshop.

Each year in the U.S., nearly 250,000 women die of ischemic heart disease, and roughly 100,000 deaths occur before the average life expectancy, making it the leading killer of women (1). Although recent data demonstrate that rates of cardiac catheterization and diagnosis of nonfatal ischemic heart disease have doubled among women in the last decade (2), ischemic heart disease in women is still identified less often (3,4) and at a more advanced stage (5), and treated less aggressively (4,6) compared with that in men. Women with ischemic heart disease also have a worse prognosis compared with their male counterparts (7,8), suggesting that gender-related differences in disease detection and treatment may influence prognosis.
Accurate and timely diagnosis of ischemic heart disease in women is a major challenge to physicians. At least three problematic areas exist:

Symptom recognition: Women have a higher frequency of chest pain than men, yet have a lower prevalence of epicardial coronary artery stenoses (9). Chest pain/discomfort characteristic for angina is a less specific marker for ischemic heart disease in women compared with that in men (10). Gender-specific ischemic heart disease symptom tools are not available.

Diagnostic testing: Electrocardiographic (ECG) abnormalities, including rest- and exercise-induced changes indicative of ischemic heart disease, are believed to be more often “falsely positive” in women than in men (11). Myocardial perfusion (3), hemodynamic and ventriculographic response (12) to exercise is more commonly abnormal among women, without evidence of epicardial coronary artery stenoses, compared with that among men. Prognosis in women with symptoms and abnormal diagnostic tests but no coronary stenoses is largely unknown. Existing diagnostic testing modalities for both epicardial coronary artery disease and microvascular dysfunction are suboptimal in women.

Reproductive hormonal status: Diagnostic testing for ischemic heart disease in women demonstrates higher levels of test variability compared with that in men (13). Cycling reproductive hormones may account for this variability. Effects of fluctuating estrogen levels on vascular smooth muscle and coronary artery vasoemotion have been postulated as explanations for why women have a higher frequency of chest pain and more frequent false positive stress test results in the absence of epicardial coronary artery disease compared with men. Experimental data show that estrogen affects coronary artery vasoemotion (14). The role reproductive hormones play in symptom manifestation and ischemic heart disease diagnostic testing is largely unknown.

The Women’s Ischemia Syndrome Evaluation (WISE) is a National Heart, Lung and Blood Institute–sponsored, four-center study designed to address ischemic heart disease recognition and diagnosis. The primary objectives of the WISE are: 1) to improve diagnostic testing for ischemic heart disease in women, including symptom evaluation tools, risk assessment algorithms and noninvasive imaging techniques; 2) to study pathophysiologic mechanisms and prognosis in women with chest pain and abnormal diagnostic testing for myocardial ischemia in the absence of epicardial coronary artery stenoses, and 3) to evaluate the influence of cyclical hormones, menopausal status and reproductive hormone levels on symptoms and diagnostic testing results.

METHODS

The WISE study design brings together a variety of expertise (Appendix) to assess different but complementary innovative diagnostic tests in four clinical sites. A common core protocol used by all four sites is itemized in Table 1. Individual site protocols include complementary physiologic and functional cardiovascular assessments (Table 2). The study protocols were each approved by the site institutional review boards. All women are followed for at least one year to assess clinical events and symptom status.

The study is organized into three phases. Phase I (1996–1997) was a pilot phase and enrolled 256 women. Data from the common core protocol as well as individual site protocols for this phase have been examined and protocol revisions were made before proceeding to Phase II. Phase II (1997–1999) is studying an additional 680 women, with a total WISE enrollment of 936 women. Phase III (2000) will
include patient follow-up, data analysis and a National Institutes of Health WISE workshop.

**Study Recruitment and Inclusion/Exclusion Criteria**

Women are eligible for participation if they are older than 18 years of age and are undergoing a clinically indicated coronary angiogram as part of their regular medical care for chest pain symptoms or suspected myocardial ischemia. Major exclusion criteria include comorbidity which compromises one-year follow-up, pregnancy, contraindications to provocative diagnostic testing, cardiomyopathy, New York Heart Association class IV congestive heart failure, recent myocardial infarction, significant valvular or congenital heart disease and a language barrier to questionnaire testing. Women with recent coronary angioplasty or coronary bypass surgery or who undergo these procedures after angiography but before their WISE testing are also excluded.

**Common Core Protocol**

All participants have data collected uniformly for a Common Core Protocol, as outlined in Figure 1. To characterize symptoms, WISE compares a questionnaire of known diagnostic validity in women (15) to a new symptom questionnaire specifically developed for women (Hodgson and Berry, personal communication, August 1996). Questions regarding initial response to symptoms and health seeking behavior are included. Symptoms provoked during testing procedures are assessed using a uniform tool. Psychosocial assessment includes indicators of hostility/cynicism (16), typical depression (17), panic (18), avoidance (19), autonomic perception (20), reward dependence (21), trait anxiety (22), social support (23) and quality of life. Blood determinations include follicle-stimulating hormone, luteinizing hormone, progesterone, estradiol, bioavailable estradiol, estrone, phytoestrogens, fasting blood glucose, lipids, homocysteine, lipid peroxidation and deoxyribonucleic acid analysis.

Coronary angiography as assessed by a core laboratory includes quantification of epicardial coronary artery size, quantification of left ventricular ejection fraction and qualitative and quantitative assessment as to the presence, severity and complexity of epicardial coronary artery stenoses, using a previously published coronary severity score (24). The following definitions are used for coronary artery group categorization: normal/minimal disease = <20% stenosis; mild = 20% to 49% stenosis; significant = ≥50% stenosis in any one major epicardial coronary artery. Resting ECGs are interpreted by a core laboratory, using...
gender-specific interpretative criteria for left ventricular hypertrophy (25). Data are also being collected, when available, from routine clinical stress testing, including nuclear perfusion imaging, performed before WISE enrollment.

Ambulatory ECG monitoring is performed for 24 to 48 h according to previously described methods (26), using an all-digital recording system (27,28) with electronic transfer of the data to a core laboratory for analysis and interpretation. Brachial artery reactivity testing for both endothelium-dependent and endothelium-independent vasomotion is performed using standard techniques (29), with data analysis by a core laboratory.

**Follow-up**

Women’s Ischemia Syndrome Evaluation participants are contacted at six weeks and then annually to assess symptom status, menstrual status and occurrence of cardiovascular events, including death, nonfatal myocardial infarction, coronary angioplasty, coronary bypass surgery, cardiac transplantation and hospitalization for unstable angina.

**Specific Protocols**

The testing protocol methods are organized below according to the three main WISE study goals. When testing is performed at more than one site, a uniform protocol is used. Interpretation of all studies is performed by masked observers for both qualitative and quantitative analysis.

**Goal: to improve diagnostic testing for ischemic heart disease in women.** The innovative diagnostic tests selected for the WISE represent the best technologic advances in ischemic heart disease detection currently available. An emphasis was placed on selection of techniques which might obviate difficulties relevant to women, such as breast imaging artifact (magnetic resonance imaging [MRI]–coronary angiography, MRI perfusion imaging and sestamibi single photon emission computed tomography [SPECT] perfusion imaging), as well as techniques commonly available currently (dobutamine stress echocardiography and exercise stress testing).

**MAGNETIC RESONANCE IMAGING PERFUSION IMAGING.** Magnetic resonance imaging myocardial perfusion imaging is performed using “first pass” gadolinium–diethylenetriaminepenta-acetic acid and a 1.5-T Philips ACS Gyroscan system (Best, The Netherlands). Cardiac scout images (two- and four-chamber views) are acquired in two orthogonal planes and dynamic imaging is initiated just before the bolus of gadolinium and continues for 64 heartbeats. The BRISK (30) and interpolated keyhole (31) imaging sequences developed by one of the sites (University of Alabama at Birmingham) allow up to three or four near-simultaneous short-axis images to be acquired during each cardiac cycle. Imaging of left ventricular function is also performed. Qualitative defects by MRI are determined by describing regional signal intensity with that of the region containing the highest signal intensity in predefined regions. Quantitative analysis uses plots of MR signal intensity versus location about the circumference of the short-axis image.

**SESTAMIBI SPECT IMAGING.** Sestamibi SPECT myocardial imaging is performed at baseline and during dipyridamole infusion. Myocardial perfusion images are obtained on a 64 × 64 matrix using a single-head Siemens Orbitor SPECT camera (Schaumberg, Illinois) with a high resolution parallel-hole collimator for sestamibi imaging. Imaging is performed every 5° for 40 s over a 180° arc. Rest and dipyridamole images with sestamibi are obtained 1 h after injection. Qualitative and quantitative analyses are performed, the latter using gender-specific normal limits.

**DOBUTAMINE STRESS ECHOCARDIOGRAPHY.** After acquisition of baseline images in standard views, dobutamine stress echocardiography is performed using published methodology (32). Image analysis includes calculation of a wall motion score index, which is the total score divided by the number of segments visualized and scored.

**EXERCISE STRESS ECG.** After standard 12-lead ECG recordings and blood pressure measurements at rest, the Asymptomatic Cardiac Ischemia Pilot treadmill exercise protocol is performed, since it provides continuous “ramp-like” increases in work, using previously published methods (26). Reports of symptoms, including chest pain or discomfort, are carefully elicited and recorded along with level of perceived exertion using the Borg scale (33).

**Goal: to study pathophysiologic mechanisms for ischemia in the absence of epicardial coronary artery stenoses.** Testing protocols were designed to determine the prevalence of this syndrome in women with normal or mild stenoses using a reference standard test for ischemia (MR spectroscopy) and to explore the pathophysiologic mechanisms involved (microvascular coronary flow reserve and endothelial function testing).

**MAGNETIC RESONANCE SPECTROSCOPIC STUDY.** $^{31}$Porous MR spectroscopy is a nonimaging direct biochemical
assessment of phosphocreatine, adenosine triphosphate and inorganic phosphate metabolites. The patient is placed supine in a Philips 1.5-T ACS MRI system (Best, The Netherlands), and the positioning of the $^{31}$P surface coil over the heart is confirmed. After acquisition of a control spectrum at rest, the subject squeezes and holds a handgrip at 30% of maximum force for approximately 7 min, during which time a second spectrum is obtained. After the period of exercise, the subject is allowed to recover, another spectrum is collected and the study is complete. Spectral data are processed at a core laboratory using Philips software, and include phosphocreatine/adenosine triphosphate ratios and rate–pressure products during all phases as well as average dynamometer output for the exercise phase.

MICROVASCULAR CORONARY FLOW RESERVE. In women with normal or mild stenoses, the left anterior descending coronary artery is uniformly studied. When appropriate, the artery suspected as causing the abnormal diagnostic test response is studied. After administration of systemic heparin, a 0.014- to 0.018-in. (0.036 to 0.046 cm) Doppler-tipped guide wire is advanced into the target vessel, as previously described (14). After baseline recordings, adenosine (18 μg diluted in 2 ml saline followed by 5 ml saline flush) is hand-injected as a bolus via the coronary guiding catheter, and recordings are repeated. Time-averaged peak coronary blood flow velocity is assessed at baseline and after intracoronary adenosine and nitroglycerin (200 μg). One site (University of Pittsburgh) is also assessing this during a speech mental stress task and intravenous adenosine. A cineangiogram is performed immediately after measurement of coronary blood flow velocity. Quantitative coronary angiography is performed off-line to quantify epicardial coronary cross-sectional area 5.2 mm distal to the guide wire tip. Coronary flow reserve is computed as the ratio of post- to preadenosine average peak velocity (14). Volumetric blood flow calculations, using coronary lumen diameter measured from the angiograms, is also performed using previously reported techniques (34). The ratio of flow during each intervention (speech task, intracoronary and intravenous adenosine, intracoronary nitroglycerin) to baseline is used as a standard to define coronary vasomotion in the studied women.

CORONARY ARTERY ENDOTHELIAL FUNCTION. Two minutes after completion of maximum flow reserve (described above), repeat baseline recordings are made. The infusion catheter is primed with low dose (10$^{-6}$M) acetylcholine (0.036 μg/ml). Acetylcholine is then infused at a rate of 2 ml/min for 3 min. Three minutes after the beginning of the infusion, blood flow velocity, ECG and pressure recordings are obtained, and a left coronary cineangiogram is recorded using hand-injected low osmolar, nonionic contrast material. The same volumes of contrast material and the same optimal projection are used for each angiogram. High dose (10$^{-4}$M) acetylcholine (3.5 μg/ml) is then infused and after 3 min all recordings and an angiogram are repeated. Five minutes after this, coronary flow velocity and coronary angiography are obtained. Intracoronary nitroglycerin (150 μg) is given as a bolus from a glass syringe through the guide catheter. After 1 min, coronary angiography is performed. Nitroglycerin is given last as a direct acting
dilator to counteract any residual vasoconstrictive effects of acetylcholine and to assure a reference angiogram for analysis of maximal coronary lumen diameter at each coronary segment of interest.

**POSITRON EMISSION TOMOGRAPHY IMAGING.** Baseline myocardial perfusion is quantified in each of the three coronary artery distributions by $^{13}$N-NH$_3$-positron emission tomography imaging using standard techniques (35,36). Twenty millicuries of $^{13}$N-NH$_3$ is injected at rest, during a continuous infusion of intravenous adenosine (140 μg/kg/min), and during performance of a mental stress speech task. The speech task uses predetermined stress-provoking scenarios (37), and consists of a 2-min preparation period followed by a 3-min speech. The first several minutes of temporal data acquired as $^{13}$N-NH$_3$ is distributed in the blood and myocardium are analyzed by a previously validated two-compartment model to quantify myocardial blood flow (38,39).

**Goal:** to evaluate the influence of menopausal status and reproductive hormone levels on diagnostic testing results. This testing is designed to assess diagnostic test reproducibility in women, determine sources of variability, such as cyclical reproductive hormones, and investigate the influence of reproductive hormonal status and hormone therapy on diagnostic test response and symptomatic status.

**HORMONAL STATUS DETERMINATION.** The hormonal status determination developed for WISE uses both historical and single sampling blood hormonal characterization (Fig. 2). Premenopausal women also undergo menstrual cycle phase (follicular, luteal, menstrual) determination using estradiol, progesterone, follicle-stimulating hormone and luteinizing hormone levels, at the time of WISE testing. Information regarding hormone therapy, including estrogenic, progestational and androgenic agents taken within 24 h of each WISE test are recorded.

**REPRODUCIBILITY STUDIES.** A randomly chosen 3% of the WISE participants are undergoing repeat dobutamine stress echocardiography, ECG exercise stress testing, ambulatory ECG monitoring, brachial artery reactivity testing, blood sampling and quality of life assessment within six months after the initial testing period in the absence of intercurrent cardiovascular event. Careful, repeat assessment of menstrual history, hormone therapy use and blood hormone levels are carried out.

**Plan of Analysis**

The planned WISE analyses based on the three main study goals are outlined.

**Goal:** to improve diagnostic testing for ischemic heart disease in women. Analyses will determine the sets of characteristics and test results (symptom characterization, diagnostic techniques, reproductive hormone status and level) that optimally predict presence or absence of significant epicardial coronary artery stenoses, as well as outcomes (cardiac events and symptom status) during follow-up. Preliminary modeling for this has begun with data from patients entered into Phase I. This allows for assessment of necessity for transforming data, and assessment of stability of the models by comparing the model for Phase I with the model for Phase II, and provides focus for analyses to be performed when all data are available. Estimates of sensitivity, specificity and predictive accuracy from derived indexes will have 95% confidence intervals no wider than ±7%, based on a minimum clinically defined subgroup sample size of 200 for specific diagnostic tests. Due to the referral nature of this symptomatic population, selection bias(es) will be present which will probably influence conclusions regarding the various tests’ diagnostic accuracy.

**Goal:** to study pathophysiologic mechanisms and prognosis of myocardial ischemia in the absence of epicardial coronary artery disease. Women with evidence of myocardial ischemia by $^{31}$P MR spectroscopy in the absence of significant epicardial coronary artery stenoses will be compared with women without evidence of myocardial ischemia, as well as with women with significant epicardial coronary artery stenoses according to physiologic measures such as coronary flow reserve and endothelial function. Hormonal status, symptoms and psychosocial characteristics will also be compared to explore potential pathophysiologic mechanisms of myocardial ischemia in the absence of epicardial coronary artery stenoses. Prediction of cardiovascular events, as previously defined, during the 1- to 3-year follow-up will include comparison of those with and without significant epicardial coronary artery stenoses and/or myocardial ischemia. The estimated population of 200 participants with myocardial ischemia by MR spectroscopy is expected to have a relatively low annual event rate (<2%) compared with the approximately 300 participants with significant epicardial coronary artery disease with an estimated cumulative event rate of 20%. Since these rates are not likely to provide sufficient power to detect meaningful differences in prognosis by baseline assessment, an extension in the long-term follow-up of WISE participants is being planned.

**Goal:** to evaluate the influence of menopausal status and reproductive hormone levels on diagnostic testing results. Reproductive hormonal status (premenopausal, perimenopausal, postmenopausal and hormone replacement therapy) and serum hormone levels will be analyzed as to their influence on diagnostic test accuracy and reproducibility. Reproductive status and hormone levels will be analyzed as to their influence on symptoms, as well as measures of coronary flow, endothelial function and myocardial ischemia measured by $^{31}$P MR spectroscopy. These measures will be compared among hormonal status groups using analysis of variance with factors of hormonal status and diagnostic test results. Diameter change will also be related directly to estrogen levels as well as to symptoms, the presence and
magnitude of myocardial perfusion abnormalities, coronary arterial microvascular and endothelial testing and hormonal status using scatterplots and regression analyses.

RESULTS

Characteristics of the pilot phase participants. A total of 1,979 women were screened, of whom 450 (23%) were eligible for study entry during the pilot phase between November 15, 1996 and July 16, 1997. The three most frequent exclusions were recent revascularization procedures (n = 257, 21%), contraindications to ischemia provocation (n = 254, 21%) and recent myocardial infarction (n = 154, 12%). Among the 249 (55%) enrolled women, 23 (9%) of subjects have been terminated from the study for reasons that included revascularization procedures after study entry but before WISE testing, contact with patient lost and patient found to be ineligible/refused testing. There were three deaths remote from the WISE protocol testing.

Characteristics for the initial 308 WISE participants are listed in Table 3. These women with suspected ischemic heart disease are compared with previously described populations of women, including healthy women from the Framingham Study (40), healthy postmenopausal women from the Postmenopausal Estrogen/Progestin Interventions study (41) and postmenopausal women with established ischemic heart disease from the Heart and Estrogen/ Progestin Replacement Study (42). Table 3 documents that the WISE protocol identifies a group of women with a constellation of cardiac risk factors greater than that seen in both healthy women and women with established ischemic heart disease. Notably, minority recruitment is good at 21%.

Review of reproductive status demonstrates that 85% of the pilot phase WISE participants were postmenopausal, 3% were perimenopausal and 11% were premenopausal. Among these participants, 38% were current users of hormone replacement therapy. Among the postmenopausal women, 60% reported prior hysterectomy and among these women, 50% also reported bilateral salpingo-oophorectomy.

Characterization of the chest pain symptoms revealed that 35% reported typical angina, 60% reported atypical angina and 45% reported daily/almost daily symptoms. Ninety-one percent of the participants had a low functional capacity of <8 metabolic equivalents, measured by the Duke Activity Score Index (43). Comorbid conditions are frequent and included history of treatment for depression (26%), autoimmune disease (20%), weight cycling (>10 lbs [>4.54 kg] 3 times) (32%) and polycystic ovary disease (8%).

Coronary angiography results in the first 323 WISE participants revealed that 31% of the participants have significant coronary artery stenoses (≥50%) in any major coronary artery, 32% have mild stenoses (20% to 49%) and 37% have no (<20%) stenoses. The cumulative frequency distribution of the severity scores in the WISE participants is depicted in Figure 3, and demonstrates that 50% have a low severity score <10. The average left ventricular ejection fraction is 68% (range 23% to 86%), and the majority (87%) are greater than 50%.

Table 3. Comparative Characteristics—WISE Phase I

<table>
<thead>
<tr>
<th>Variable</th>
<th>Healthy Women, Framingham—Women</th>
<th>Menopausal, PEPI (41)</th>
<th>Menopausal/CAD, HERS (42)</th>
<th>Suspected CAD, WISE—Phase I</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr) (range)</td>
<td>49 (19–78)</td>
<td>56 (45–64)</td>
<td>67 (44–79)</td>
<td>59 (21–86)</td>
</tr>
<tr>
<td>Minority</td>
<td>0%</td>
<td>11%</td>
<td>11%</td>
<td>21%</td>
</tr>
<tr>
<td>&gt;High school</td>
<td>NA</td>
<td>82%</td>
<td>32%</td>
<td>35%</td>
</tr>
<tr>
<td>HTN</td>
<td>22%</td>
<td>6%</td>
<td>58%</td>
<td>57%</td>
</tr>
<tr>
<td>DM</td>
<td>2%</td>
<td>0.5%</td>
<td>19%</td>
<td>23%</td>
</tr>
<tr>
<td>Smoke</td>
<td>30%</td>
<td>13%</td>
<td>13%</td>
<td>20%</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>25 ± 5</td>
<td>26 ± 5</td>
<td>28</td>
<td>30 ± 6</td>
</tr>
<tr>
<td>SBP (mm Hg)</td>
<td>121 ± 18</td>
<td>115 ± 14</td>
<td>135 ± 14</td>
<td>138 ± 23</td>
</tr>
<tr>
<td>DBP (mm Hg)</td>
<td>77 ± 10</td>
<td>72 ± 8</td>
<td>73 ± 10</td>
<td>77 ± 13</td>
</tr>
<tr>
<td>FBS (mg/dl)</td>
<td>92 ± 21</td>
<td>97 ± 10</td>
<td>NA</td>
<td>118 ± 53</td>
</tr>
<tr>
<td>TC (mg/dl)</td>
<td>207 ± 43</td>
<td>224 ± 30</td>
<td>NA</td>
<td>200 ± 49</td>
</tr>
<tr>
<td>TG (mg/dl)</td>
<td>106 ± 123</td>
<td>104 ± 55</td>
<td>168 ± 64</td>
<td>153 ± 93</td>
</tr>
<tr>
<td>LDL-C (mg/dl)</td>
<td>59 ± 14</td>
<td>63 ± 16</td>
<td>50 ± 13</td>
<td>53 ± 13</td>
</tr>
<tr>
<td>TG/TC</td>
<td>3.9 ± 0.14</td>
<td>4.7 ± 1.5</td>
<td>3.9 ± 1.3</td>
<td></td>
</tr>
<tr>
<td>HRT</td>
<td>NA</td>
<td>100%</td>
<td>100%</td>
<td>86%</td>
</tr>
<tr>
<td>HRT</td>
<td>0%</td>
<td>24%*</td>
<td>38%</td>
<td></td>
</tr>
</tbody>
</table>

*BMI = body mass index; CAD = coronary artery disease; DBP = diastolic blood pressure; DM = diabetes mellitus (medication or FBS >140 mg/dl); FBS = fasting blood sugar; HDL-C = high density lipoprotein cholesterol; HERS = Heart and Estrogen/Progestin Replacement Study; HRT = hormone replacement therapy; HTN = hypertension (medication or SBP >140 mm Hg or DBP >95 mm Hg); LDL-C = low density lipoprotein cholesterol; NA = not available; PEPI = Postmenopausal Estrogen/Progestin Interventions; SBP = systolic blood pressure; Smoke = current smoking; TC = total cholesterol; TG = triglycerides; WISE = Women’s Ischemia Syndrome Evaluation.
DISCUSSION

Initial pilot phase data indicate that the WISE protocol is safe and feasible for identifying symptomatic women with and without significant epicardial coronary artery stenoses. Pilot data indicate that WISE participants have high frequency of coronary artery disease risk factors and experience symptoms that are limiting, despite often minimal epicardial coronary artery stenoses and preserved left ventricular function.

Summary. Previous evidence suggests that gender-specific differences exist in ischemic heart disease symptoms, detection and management. The WISE study is: 1) defining new, comprehensive diagnostic strategies to evaluate women with suspected ischemic heart disease; 2) exploring the pathophysiology and significance of ischemia in the absence of epicardial coronary stenoses, and 3) evaluating the role of reproductive hormones on symptoms and diagnostic test response. Phase II of the WISE is in progress.

APPENDIX: WISE PARTICIPANTS

Clinical Sites and Investigators

Allegheny General Hospital - MCP Hahnemann School of Medicine, Pittsburgh: Nathaniel Reichek, MD (principal investigator [PI]), Christopher Kramer, MD (coinvestigator [CoI]), Douglas Schulman, MD (CoI), Sinda Dianzumba, MD (CoI), Walter Rogers, MS (CoI), Bryan C. Donohue, MD (CoI), James Joye, DO (CoI), Diane Vido (ordinator [C]), Diana Lynn Pakstis, RN(C)

University of Alabama at Birmingham, Birmingham: William J. Rogers, MD (PI), Gerald M. Pohost, MD (CoI), Alfred A. Bartolucci, PhD (CoI), Vera Bittner, MD (CoI), Joseph R. Logic, MD (CoI), Steven Buchthal, PhD (CoI), Carol E. Cornell, PhD (CoI), Jan A. Denhollander, PhD (CoI), Marc Doyle, PhD (CoI), Anthon R. Fuisz, MD (CoI), Edward T. Martin, MD (CoI), Thomas D. Paine, MD (CoI), Michelle L. Robbin, MD (CoI), Lindsey Tauxe (CoI), Edward G. Walsh, PhD, MSPH (CoI), Kathy Clay, RN(C), William C. Gamble III, RN(C), Kathleen Armstrong, RN(C)

University of Florida, Gainesville: Carl J. Pepine, MD (PI), Jannet Lewis, MD (CoI), Lang Lin, MD (CoI), Eileen Handberg-Thurmond, PhD (CoI), Rick Kerensky, MD (CoI), Keith Stone, MD (CoI), Susan McGorray, PhD (CoI), Alix Baxter, MD (CoI), Alice Boyette (C)

University of Pittsburgh: Steven E. Reis, MD (PI), Katherine Detre, MD, DrPH (CoPI), Richard Holubkov, PhD (CoI), Flordeliza Villanueva, MD (CoI), Jane Owens, PhD (CoI), Karen Matthews, PhD (consultant), Janine Flory, PhD (CoI), A.J. Conrad Smith, MD (CoI), Daniel Edmundowicz, MD (CoI), David Townsend, PhD (CoI), Carolyn Meltzer, MD (CoI), Kathleen Zell, BSN (C), Cheryl Rickens, RN(C)

Coordinating Center—University of Pittsburgh: Sheryl F. Kelsey, PhD (PI), Katherine M. Detre, MD, DrPH (CoPI), Richard Holubkov, PhD (CoI), Tanya Kenkre, MPH(C), Marian Olson, MS(C), B. Delia Johnson, PhD(C)

Core Angiography Laboratory—Rhode Island Hospital: Barry L. Sharaf, MD (PI), David O. Williams, MD (CoI), Nicholas Miele (C)

National Heart, Lung, and Blood Institute Project Officers: George Sopko, MD, Paul Albert, PhD, Gail Pearson, MD, Donna Berkowitz (contract C), William Stevens (contract C), Doug Frye (contract C)

Study Chair—Cedars-Sinai Medical Center, Los Angeles: C. Noel Bairey Merz, MD (PI)

Data and Safety Monitoring Board: Bernard J. Gersh, MD (Chair), Robert O. Bonow, MD, Richard O. Cannon III, MD, Katherine Stoney, PhD, Madison Powers, PhD, JD, Erica Brittain, PhD

Reprint requests and correspondence: Dr. C. Noel Bairey Merz, c/o WISE Coordinating Center, University of Pittsburgh, 127 Parran Hall, Graduate School of Public Health, 130 DeSoto St., Pittsburgh, Pennsylvania 15261.

REFERENCES


